Insulin glargine biosimilar comes up trumps

An experimental insulin gargline biosimilar developed by Merck is just as safe and effective as the originator product Lantus, a phase 3 trial has found.

The study randomised 500 type 1 patients either to the biosimilar, known as MK-1293, or to Lantus, the only insulin gargline product currently available on the PBS.

The mean difference in A1c levels was 0.04%, which met non-inferiority criteria.